Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV7Q6X)

Drug Name

APN-201 Drug Info

Synonyms

Lipoxysan; Liposomal SOD (wound healing), Polymun; Liposomal SOD (Peyronie's disease), Polymun; RhSOD (liposomal, dermatitis), Apeiron; Liposomal superoxide dismutase (recombinant, encapsulated, topical), Polymun

Indication

Disease Entry	ICD 11	Status	REF
Dermatitis	EA80-EA89	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DMV7Q6X

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Superoxide dismutase Cu-Zn (SOD Cu-Zn)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofersen	DM0AEDT	Amyotrophic lateral sclerosis	8B60.0	Approved	[3]
Coprexa	DMA0WEK	Neurological disorder	6B60	Phase 3	[4]
Tempol	DMUQH78	Spinal cord injury	ND51.2	Phase 2	[5]
Superoxide dismutase	DMSWPA6	Myocardial infarction	BA41-BA43	Phase 2	[6]
Midismase	DMGCRKY	Cerebral infarction	8B11.5Z	Phase 2	[7]
Methoxyestradiol	DMHSL87	N. A.	N. A.	Phase 2	[8]
ATN-224	DMQJ5DV	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
PC-SOD	DMUHDX3	Interstitial lung disease	CB0Z	Phase 2	[7]
EUK-189	DMY9ZAS	Skin burns	ME65.0	Phase 1	[9]
AEOL-10150	DM13YRT	Multiple sclerosis	8A40	Preclinical	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Superoxide dismutase Cu-Zn (SOD Cu-Zn)	TT6RVLG	SODC_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01513278) Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer. U.S. NationalInstitutes of Health.
2	Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
5	The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34.
6	Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36.
7	A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
8	Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14.
9	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
10	AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006 Jan;7(1):70-80.